Pfizer to Cut 300 Jobs as Alzheimer’s, Parkinson’s Research Ends

The Pfizer Inc. logo is seen on the lab coat of an employee at the company's research and development facility in Cambridge, Massachusetts, U.S., on Monday, Oct. 26, 2015. Pfizer is expected to report quarterly earnings on October 27.

Photographer: Scott Eisen/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Jared S Hopkins

January 8, 2018 at 12:44 AM UTC

This article is for subscribers only.

Pfizer Inc.’s decision to stop research and development into new neuroscience drugs, including its work in Alzheimer’s and Parkinson’s diseases, will lead to about 300 job cuts.

The move to end the neuroscience-discovery program followed an internal review, the New York-based drugmaker said in an emailed statement. The job reductions will primarily affect employees at facilities in Cambridge and Andover in Massachusetts, as well as Groton, Connecticut.